{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:52:54Z","timestamp":1782492774631,"version":"3.54.5"},"reference-count":35,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["NIHR131359"],"award-info":[{"award-number":["NIHR131359"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,1,28]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Primary biliary cholangitis (PBC) is a rare chronic cholestatic disease that despite current therapy has significant ongoing unmet needs, including risks of cirrhosis and life-impairing symptoms. The current treatment approach is a step-up model, wherein first-line therapy, ursodeoxycholic acid (UDCA), is given for a minimum of 12 months before the addition of second-line therapy is considered for non-responding patients. This \u2018waiting to fail\u2019 approach, focused on the needs of low-risk patients, allows, we postulate, a key process of biliary epithelial cell (BEC) senescence to become established, driving accelerated bile duct loss and aggressive disease. Preclinical mouse modelling has shown that early use of the farnesoid X receptor agonist obeticholic acid (OCA), currently only used as second-line therapy following UDCA failure, reverses BEC senescence, changing the clinical course of disease. Here, we describe the design of the Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA) trial. The aim of OPERA is to explore a new paradigm for disease-modifying treatment of PBC: risk-informed early treatment stratification, with patients at increased risk offered UDCA and OCA combination with the goal of complete biochemical remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>OPERA is a multicentre, randomised, double-blind, placebo-controlled trial of OCA in combination with UDCA, as first-line treatment for high-risk PBC. This is a multicentre trial in England, which will be undertaken in specialist clinics in secondary\/tertiary referral centres (or as per local set up). These centres will be specialists in the area of PBC management and will manage patients from across their local region. OPERA will recruit and randomise 106 adults, within 6\u2009months of PBC diagnosis, who are at an enhanced risk of non-response to standard first-line therapy, between either: (1) UDCA and OCA or (2) UDCA and matched placebo in a 1:1 ratio. The primary efficacy outcome measure is the percentage of participants showing normalisation of serum alkaline phosphatase and total bilirubin values at 26 weeks (disease remission).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Favourable ethical opinion was received from London \u2013 Riverside Research Ethics Committee (reference: 22\/LO\/0878). Potential participants will be fully informed of their rights and the benefits and harms of the trial by the research team before giving informed consent to participate in the trial. Results will be disseminated in peer-reviewed publications, at national and international conferences, in peer-reviewed journals and to participants and the public (using lay language).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN17176388\">ISRCTN17176388<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-113812","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:40:13Z","timestamp":1773254413000},"page":"e113812","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"isrctn17176388","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1901-3931","authenticated-orcid":false,"given":"Sarah","family":"Dunn","sequence":"first","affiliation":[{"name":"Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7729-755X","authenticated-orcid":false,"given":"Lysbeth","family":"Evans","sequence":"additional","affiliation":[{"name":"Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2987-0977","authenticated-orcid":false,"given":"Ciara","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1139-3937","authenticated-orcid":false,"given":"Rebecca","family":"Wafer","sequence":"additional","affiliation":[{"name":"Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3217-2181","authenticated-orcid":false,"given":"Sam","family":"Moody","sequence":"additional","affiliation":[{"name":"Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-7931","authenticated-orcid":false,"given":"Faye","family":"Wolstenhulme","sequence":"additional","affiliation":[{"name":"Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1174-7892","authenticated-orcid":false,"given":"Emma","family":"Burton","sequence":"additional","affiliation":[{"name":"Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1917-7589","authenticated-orcid":false,"given":"Ann Breeze","family":"Konkoth","sequence":"additional","affiliation":[{"name":"Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8389-9140","authenticated-orcid":false,"given":"Holly","family":"Fisher","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University Faculty of Medical Sciences, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-0302","authenticated-orcid":false,"given":"Thomas","family":"Chadwick","sequence":"additional","affiliation":[{"name":"Newcastle University Institute for Health and Society, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7302-8595","authenticated-orcid":false,"given":"Annie","family":"Banham","sequence":"additional","affiliation":[{"name":"PPIE, Newcastle upon tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-7464","authenticated-orcid":false,"given":"Fiona","family":"Hale","sequence":"additional","affiliation":[{"name":"PPIE, Newcastle upon tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Christie","sequence":"additional","affiliation":[{"name":"PBC Foundation, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0415-785X","authenticated-orcid":false,"given":"Stephen T","family":"Barclay","sequence":"additional","affiliation":[{"name":"Glasgow Royal Infirmary, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6733-5225","authenticated-orcid":false,"given":"Jessica","family":"Dyson","sequence":"additional","affiliation":[{"name":"Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8303-959X","authenticated-orcid":false,"given":"Rachel","family":"Smith","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3924-4830","authenticated-orcid":false,"given":"Guruprasad","family":"Aithal","sequence":"additional","affiliation":[{"name":"Wofson Digestive Disease Centre, Queens Medical Centre University Hospital, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9644-8392","authenticated-orcid":false,"given":"Emma","family":"Culver","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5208-8185","authenticated-orcid":false,"given":"Richard","family":"Aspinall","sequence":"additional","affiliation":[{"name":"Portsmouth Hospitals University NHS Trust, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5610-5448","authenticated-orcid":false,"given":"Doug","family":"Thorburn","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Royal Free London NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5441-9064","authenticated-orcid":false,"given":"Michael","family":"Heneghan","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1494-8551","authenticated-orcid":false,"given":"Helen C","family":"Hancock","sequence":"additional","affiliation":[{"name":"Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4009-8087","authenticated-orcid":false,"given":"Palak","family":"Trivedi","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7962-5286","authenticated-orcid":false,"given":"George","family":"Mells","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-126X","authenticated-orcid":false,"given":"James","family":"Wason","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"},{"name":"MRC Biostatistics Unit, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0083-5564","authenticated-orcid":false,"given":"David E J","family":"Jones","sequence":"additional","affiliation":[{"name":"NIHR Newcastle Biomedical Research Centre and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2026062609361469000_16.3.e113812.1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1055\/s-0034-1383730","article-title":"The new epidemiology of primary biliary cirrhosis","volume":"34","author":"Griffiths","year":"2014","journal-title":"Semin Liver Dis"},{"key":"2026062609361469000_16.3.e113812.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.12.005"},{"key":"2026062609361469000_16.3.e113812.3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/apt.13794","article-title":"The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis","volume":"44","author":"Dyson","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2026062609361469000_16.3.e113812.4","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32993"},{"key":"2026062609361469000_16.3.e113812.5","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.065862"},{"key":"2026062609361469000_16.3.e113812.6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26365"},{"key":"2026062609361469000_16.3.e113812.7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22371"},{"key":"2026062609361469000_16.3.e113812.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.11.021"},{"key":"2026062609361469000_16.3.e113812.9","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.cgh.2020.06.025","article-title":"Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom","volume":"19","author":"Rice","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026062609361469000_16.3.e113812.10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026062609361469000_16.3.e113812.11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319057"},{"key":"2026062609361469000_16.3.e113812.12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.029"},{"key":"2026062609361469000_16.3.e113812.13","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308351"},{"key":"2026062609361469000_16.3.e113812.14","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrgastro.2015.187","article-title":"Primary biliary cirrhosis: Renaming primary biliary cirrhosis-clarity or confusion?","volume":"12","author":"Trivedi","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026062609361469000_16.3.e113812.15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/MCG.0000000000001120","article-title":"Factors Associated With Potential Progressive Course of Primary Biliary Cholangitis: Data From Real-world US Database","volume":"53","author":"Younossi","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"2026062609361469000_16.3.e113812.16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104068","article-title":"The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study","volume":"80","author":"Jones","year":"2022","journal-title":"EBioMedicine"},{"key":"2026062609361469000_16.3.e113812.17","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2395"},{"key":"2026062609361469000_16.3.e113812.18","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/liv.14534","article-title":"A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis","volume":"40","author":"Yagi","year":"2020","journal-title":"Liver Int"},{"key":"2026062609361469000_16.3.e113812.19","unstructured":"Obeticholic acid for treating primary biliary cholangitis (2017) Technology appraisal guidance TA443. National Institute for Health Care Excellence; 2017. Available: https:\/\/www.nice.org.uk\/guidance\/ta443"},{"key":"2026062609361469000_16.3.e113812.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509840"},{"key":"2026062609361469000_16.3.e113812.21","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/liv.15592","article-title":"Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival","volume":"43","author":"Murillo Perez","year":"2023","journal-title":"Liver Int"},{"key":"2026062609361469000_16.3.e113812.22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.26322","article-title":"Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study","volume":"58","author":"Zhang","year":"2013","journal-title":"Hepatology"},{"key":"2026062609361469000_16.3.e113812.23","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.cgh.2022.07.038","article-title":"UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis","volume":"21","author":"Abbas","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026062609361469000_16.3.e113812.24","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1002\/hep.32011","article-title":"The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis","volume":"74","author":"Barron-Millar","year":"2021","journal-title":"Hepatology"},{"key":"2026062609361469000_16.3.e113812.25","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-020-04353-8","article-title":"Analysis of responder-based endpoints: improving power through utilising continuous components","volume":"21","author":"Wason","year":"2020","journal-title":"Trials"},{"key":"2026062609361469000_16.3.e113812.26","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2026062609361469000_16.3.e113812.27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.gcb.2010.07.018","article-title":"The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis","volume":"35","author":"Kuiper","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2026062609361469000_16.3.e113812.28","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/apt.15533","article-title":"Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response","volume":"50","author":"Murillo Perez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026062609361469000_16.3.e113812.29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ebiom.2016.11.021","article-title":"Early Molecular Stratification of High-risk Primary Biliary Cholangitis","volume":"14","author":"Hardie","year":"2016","journal-title":"EBioMedicine"},{"key":"2026062609361469000_16.3.e113812.30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2023.100931","article-title":"Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery","volume":"6","author":"Abbas","year":"2024","journal-title":"JHEP Rep"},{"key":"2026062609361469000_16.3.e113812.31","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s10620-018-5074-8","article-title":"Are Clinicians Ready for Safe Use of Stratified Therapy in Primary Biliary Cholangitis (PBC)? A Study of Educational Awareness","volume":"63","author":"Jopson","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2026062609361469000_16.3.e113812.32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajpath.2022.09.005","article-title":"Anti-Cholestatic Therapy with Obeticholic Acid Improves Short-Term Memory in Bile Duct-Ligated Mice","volume":"193","author":"Gee","year":"2023","journal-title":"Am J Pathol"},{"key":"2026062609361469000_16.3.e113812.33","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S2468-1253(18)30177-8","article-title":"Ensuring timely treatment of patients with primary biliary cholangitis","volume":"3","author":"Marschall","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026062609361469000_16.3.e113812.34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","article-title":"Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?","volume":"79","author":"Corpechot","year":"2024","journal-title":"Hepatology"},{"key":"2026062609361469000_16.3.e113812.35","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/HEP.0000000000000864","article-title":"Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?","volume":"80","author":"Jones","year":"2024","journal-title":"Hepatology"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-113812","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:40:22Z","timestamp":1782492022000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-113812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,11]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjopen-2025-113812"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-113812","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}